MURA
Mural Oncology plc
$2.09
-$0.01(-0.48%)
65
Overall
80
Value
50
Tech
--
Quality
Market Cap
$36.42M
Volume
73.06K
52W Range
$0.95 - $4.74
Target Price
$13.00
Company Overview
| Mkt Cap | $36.42M | Price | $2.09 |
| Volume | 73.06K | Change | -0.48% |
| P/E Ratio | -0.3 | Open | $2.09 |
| Revenue | -- | Prev Close | $2.10 |
| Net Income | $-128.5M | 52W Range | $0.95 - $4.74 |
| Div Yield | N/A | Target | $13.00 |
| Overall | 65 | Value | 80 |
| Quality | -- | Technical | 50 |
No chart data available
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Latest News
Mural Oncology Approves Acquisition by XRA 5 Corp.
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MURA | $2.09 | -0.5% | 73.06K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |